Healthcare
Psyence Group Inc.(PSYGF)
Live Price
Offline$0.127
+0.00% today
1Y Change
+9.01%
Window
Jun 25, 2025 โ May 28, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +91.8%
- Dividend Yield
- 0.0%
Coverage: 231 bars ยท Jun 25, 2025 โ May 28, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Psyence Group Inc. (PSYGF) is a Healthcare stock with listed on OTC. The stock last traded around $0.13 and up 9.0% across the available one-year price window (Jun 25, 2025 โ May 28, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +91.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +91.8%, free cash flow +5.8% with operating margin 0.0% and ROIC -417.9%. Stock Foundry combines PSYGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2024 was reported on Dec 31, 2024, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +91.8%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2024 Dec 31, 2024 | โ | +0.0% | +0.0% | +0.0% |
2024 Sep 30, 2024 | โ | +0.0% | +0.0% | +0.0% |
2024 Jun 29, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSYGF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PSYGF Max Drawdown
-14.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PSYGF and SPY.
Company Overview
Psyence Group Inc.
Other OTC
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
- Leadership
- Jody Aufrichtig
- IPO Date
- May 31, 2022
- Street Address
- 200 Bay Street
- Mailing
- Toronto, ON, M5J 2J1
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- +1 416 477 1708
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.2
Growth
- Revenue
- 0.0%
- EPS
- +91.8%
- Free Cash Flow
- +5.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 303.8%
- ROIC
- -417.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 16.88
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.